The DNM1 Gene Early Infantile Epileptic Encephalopathy Type 31 Genetic Test is a specialized diagnostic examination offered by DNA Labs UAE, designed to detect mutations in the DNM1 gene, which have been associated with Early Infantile Epileptic Encephalopathy Type 31 (EIEE31). This condition is a severe form of epilepsy that manifests in infancy and is characterized by frequent seizures and significant developmental delays. The test plays a crucial role in the early identification of this genetic disorder, enabling healthcare providers to initiate appropriate treatment and management strategies as early as possible.
The testing process involves collecting a DNA sample from the patient, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory for any genetic abnormalities in the DNM1 gene. Positive identification of mutations can help in confirming the diagnosis of EIEE31, facilitating a better understanding of the condition's progression and the potential response to various treatment options.
The cost of the DNM1 Gene Early Infantile Epileptic Encephalopathy Type 31 Genetic Test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to detect the specific genetic mutation associated with this condition. By choosing DNA Labs UAE for this critical testing, patients and their families gain access to advanced genetic testing technology and expertise, ensuring accurate and reliable results that can significantly impact the management and outcome of the condition.
The KCNA2 gene early infantile epileptic encephalopathy type 32 genetic test is a specialized diagnostic procedure aimed at identifying mutations in the KCNA2 gene, which are associated with early infantile epileptic encephalopathy type 32 (EIEE32). This condition is a severe form of epilepsy that manifests in the first few months of life, characterized by frequent seizures and significant developmental delays. The test plays a crucial role in the early detection and management of this condition, allowing for tailored treatment plans that can improve the quality of life for affected individuals.
Performed at DNA Labs UAE, a leading facility in genetic testing, the test involves analyzing the patient's DNA to look for specific genetic alterations in the KCNA2 gene that are linked to EIEE32. This state-of-the-art lab ensures accurate and reliable results, leveraging advanced genetic sequencing technologies.
The cost of the KCNA2 gene early infantile epileptic encephalopathy type 32 genetic test at DNA Labs UAE is set at 4400 AED. This investment covers the comprehensive process of sample collection, DNA extraction, sequencing, and expert analysis, providing families with crucial information regarding the genetic underpinnings of the condition. Early diagnosis through this test can significantly impact the management strategies for affected infants, paving the way for interventions that can mitigate the severity of symptoms and promote better developmental outcomes.
The EEF1A2 gene is associated with a rare neurological disorder known as early infantile epileptic encephalopathy type 33 (EIEE33). This condition is characterized by severe seizures that begin in infancy, often accompanied by developmental delays and various neurological challenges. The EEF1A2 gene plays a crucial role in protein synthesis within cells, and mutations in this gene can disrupt normal brain function, leading to the symptoms observed in EIEE33.
To diagnose this condition and potentially guide treatment options, genetic testing can be performed to identify mutations in the EEF1A2 gene. In the UAE, DNA Labs UAE offers a specific genetic test for the EEF1A2 gene, catering to families and individuals seeking answers about this rare epileptic disorder. The test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory for the presence of mutations in the EEF1A2 gene.
The cost of the EEF1A2 gene test at DNA Labs UAE is 4400 AED. This price includes the collection of the sample, the genetic analysis, and a comprehensive report that interprets the findings. This report can be an invaluable tool for healthcare providers in diagnosing EIEE33, understanding its severity, and potentially guiding treatment decisions. Families affected by early infantile epileptic encephalopathy or those with a history of the condition may consider this test to gain more insight into their medical situation and to inform their healthcare decisions.
The STXBP1 gene is associated with early infantile epileptic encephalopathy type 4 (EIEE4), a severe neurological disorder characterized by early-onset seizures and developmental delays. Genetic testing for mutations in the STXBP1 gene is crucial for diagnosing this condition, enabling early intervention and personalized management strategies for affected individuals.
DNA Labs UAE offers a comprehensive genetic test targeting the STXBP1 gene to identify mutations that may lead to EIEE4. The test is designed to provide accurate and reliable results, which are essential for the diagnosis and treatment planning of this epileptic encephalopathy. The cost of the test is 4400 AED, reflecting the specialized nature of the analysis and the sophisticated technology employed.
By opting for this genetic test, families and healthcare providers can gain valuable insights into the genetic underpinnings of the condition, facilitating informed decisions about care and support for those affected by EIEE4.
The GUF1 gene is associated with early infantile epileptic encephalopathy type 40 (EIEE40), a severe form of epilepsy that emerges in the first months of life. This condition is characterized by frequent seizures that are resistant to treatment, developmental delays, and sometimes other neurological issues. Genetic testing for mutations in the GUF1 gene is crucial for diagnosing EIEE40, enabling targeted treatment plans and providing families with essential prognostic information.
At DNA Labs UAE, a specialized test is available for identifying mutations in the GUF1 gene that are linked to early infantile epileptic encephalopathy type 40. This test is an important tool for clinicians in the diagnosis and management of this challenging condition. The cost of the test is 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify mutations in the GUF1 gene. By offering this test, DNA Labs UAE supports healthcare providers and families in the early detection and intervention of EIEE40, potentially improving outcomes for affected infants.
The GABRB1 gene plays a crucial role in the development and function of the central nervous system. Mutations in this gene are associated with early infantile epileptic encephalopathy type 45 (EIEE45), a severe form of epilepsy that manifests in the first few months of life. This condition is characterized by frequent seizures and significant developmental delays, affecting a child's cognitive and physical growth.
To diagnose this condition accurately, genetic testing for the GABRB1 gene is available at DNA Labs UAE. The test is designed to identify mutations in the GABRB1 gene that are linked to EIEE45, providing crucial information for the diagnosis, management, and treatment of affected individuals. The test cost is set at 4400 AED, reflecting the comprehensive analysis and detailed reporting that accompanies this specialized diagnostic service.
By opting for this genetic test, parents and healthcare providers can gain valuable insights into the condition, enabling early intervention strategies that can significantly improve the quality of life for those affected by EIEE45.
The GRIN2D gene plays a crucial role in the functioning of the nervous system, encoding a subunit of NMDA receptors that are involved in synaptic transmission and plasticity in the brain. Mutations in the GRIN2D gene have been associated with early infantile epileptic encephalopathy type 46 (EIEE46), a severe form of epilepsy that manifests in infancy. This condition is characterized by frequent seizures that are resistant to treatment, developmental delays, and other neurological issues.
To diagnose this genetic condition, DNA Labs UAE offers a specialized genetic test targeting the GRIN2D gene. The test is designed to identify mutations in the GRIN2D gene that are linked to EIEE46, providing crucial information for the diagnosis and management of the condition. Early diagnosis through genetic testing can help in managing the symptoms more effectively and can guide treatment decisions.
The cost of the GRIN2D gene test at DNA Labs UAE is 4400 AED. The test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of mutations in the GRIN2D gene. Results from this test can provide valuable insights into the genetic basis of the patient's condition, aiding in the development of a personalized treatment plan.
Families with a history of EIEE46 or who have a child showing symptoms consistent with early infantile epileptic encephalopathy may consider this genetic test as part of their diagnostic journey. DNA Labs UAE ensures a comprehensive analysis, providing families and healthcare providers with critical information to support those affected by this challenging condition.
The FGF12 gene, associated with early infantile epileptic encephalopathy type 47 (EIEE47), plays a crucial role in the normal development and function of the nervous system. Mutations in the FGF12 gene can lead to severe neurological conditions characterized by early-onset seizures, developmental delays, and various other neurological abnormalities. Given the critical nature of timely and accurate diagnosis for managing such conditions, genetic testing for mutations in the FGF12 gene becomes indispensable.
DNA Labs UAE offers a specialized genetic test aimed at identifying mutations in the FGF12 gene to confirm a diagnosis of early infantile epileptic encephalopathy type 47. This test is particularly vital for families with a history of the condition or for infants presenting symptoms consistent with EIEE47. Early diagnosis through this genetic test can facilitate prompt intervention and management strategies, potentially improving outcomes and quality of life for affected individuals.
The cost of the FGF12 gene test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to detect any mutations in the FGF12 gene that could be indicative of EIEE47. Conducted in a state-of-the-art laboratory by experienced geneticists, the test adheres to stringent quality and accuracy standards, ensuring reliable results for patients and their families.
The SPTAN1 Gene Early Infantile Epileptic Encephalopathy Type 5 Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE, aimed at detecting mutations in the SPTAN1 gene. These mutations are associated with Early Infantile Epileptic Encephalopathy Type 5 (EIEE5), a rare but severe form of epilepsy that emerges in infancy. EIEE5 is characterized by frequent seizures, developmental delays, and various neurological impairments, making early diagnosis crucial for managing symptoms and improving quality of life.
This genetic test involves analyzing the patient's DNA to identify specific mutations in the SPTAN1 gene that are known to cause EIEE5. By pinpointing these mutations, healthcare providers can confirm a diagnosis of EIEE5, allowing for tailored treatment plans and genetic counseling for affected families.
The test is priced at 4400 AED and is conducted in the state-of-the-art facilities of DNA Labs UAE, ensuring high accuracy and reliability of results. This test is particularly important for families with a history of EIEE5 or unexplained infantile seizures, as it provides essential genetic insights that can guide clinical decisions and support.
The SCN1A gene is critical in the proper functioning of brain cells, and mutations in this gene can lead to a range of epileptic disorders, including Early Infantile Epileptic Encephalopathy Type 6 (EIEE6). EIEE6 is a severe form of epilepsy that emerges in the first few months of life, characterized by frequent seizures and significant developmental delays. Genetic testing for mutations in the SCN1A gene is essential for diagnosing EIEE6, guiding treatment options, and providing information on the condition's prognosis.
DNA Labs UAE offers a specialized genetic test to identify mutations in the SCN1A gene associated with Early Infantile Epileptic Encephalopathy Type 6. This test is a vital tool for families seeking answers about this challenging condition. The cost of the SCN1A gene test at DNA Labs UAE is 4400 AED. By conducting this test, healthcare professionals can confirm the diagnosis of EIEE6, enabling them to tailor a treatment plan that can potentially improve the quality of life for affected infants and provide families with crucial information regarding the condition's management and outlook.
